Home›Trial›NCT07211958
🔬NCT07211958Phase 3RECRUITING

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Study Summary

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.

Conditions
Acute Myeloid Leukemias
Interventions / Drugs
RevumenibPlaceboIntensive Chemotherapy Regimen
View on ClinicalTrials.gov ↗
Sponsor
SNDX
Syndax Pharmaceuticals
Oncology
C63/100
Study Details
Enrollment468 participants
Primary Completion—
Lead SponsorSyndax Pharmaceuticals
Data Retrieved2026-04-11 04:27:50.896963+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.